Environmental, Social And Governance Report

Overview

The report covers the Group's 2024 ESG performance across governance, pharmaceutical access and affordability, supply chain, employees, occupational safety, environmental management, and community initiatives. Highlights include RMB 986 million of annual R&D investment, 17,165 employees, 26 charity activities, and no work-related fatalities. The report also presents climate-risk analysis under IFRS S2 and a limited assurance engagement over selected 2024 KPIs by SHINEWING Sustainability Advisory Services Limited.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services